Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +2.35% | +1.65% | +12.24% | +82.81% | 54.55B | |
| -1.07% | +1.06% | +10.52% | +102.31% | 53.59B | |
| +2.59% | +0.99% | +28.07% | +57.69% | 44.75B | |
| +2.46% | -2.86% | +18.48% | +101.17% | 41.62B | |
| +0.59% | -3.11% | +223.60% | +925.83% | 39.91B | |
| +0.64% | -3.85% | +11.71% | +45.57% | 32.47B | |
| +29.01% | +48.74% | +108.67% | +95.73% | 26.7B | |
| +3.72% | -7.45% | +24.25% | -2.99% | 23.36B | |
| Average | +4.10% | -0.42% | +52.34% | +163.18% | 42.27B | |
| Weighted average by Cap. | +3.23% | -0.29% | +47.73% | +161.79% |
Employees
51
